The impact of elexacaftor/tezacaftor/ivacaftor therapy on the pulmonary management of adults with cystic fibrosis: An expert-based Delphi consensus

Role of inhaled antibiotics in the era of highly effective CFTR modulators

(2023) J. Stuart Elborn et al.   European Respiratory Review

The lung microbiota in children with cystic fibrosis captured by induced sputum sampling

(2022) Rebecca Weiser et al.   Journal of Cystic Fibrosis

Sustained effectiveness of elexacaftor-tezacaftor-ivacaftor in lung transplant candidates with cystic fibrosis

(2022) Clémence Martin et al.   Journal of Cystic Fibrosis

Effects of Elexacaftor/Tezacaftor/Ivacaftor Therapy on Lung Clearance Index and Magnetic Resonance Imaging in Patients with Cystic Fibrosis and One or Two F508del Alleles

(2022) Simon Y. Graeber et al.   AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

The Effect of CFTR Modulators on Airway Infection in Cystic Fibrosis

(2022) Caitlyn Harvey et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Standards of care for CFTR variant-specific therapy (including modulators) for people with cystic fibrosis

(2022) Kevin W. Southern et al.   Journal of Cystic Fibrosis

The Changing Epidemiology of Cystic Fibrosis

(2022) Pierre-Régis Burgel et al.   CHEST

Discontinuation versus continuation of hypertonic saline or dornase alfa in modulator treated people with cystic fibrosis (SIMPLIFY): results from two parallel, multicentre, open-label, randomised, controlled, non-inferiority trials

(2022) Nicole Mayer-Hamblett et al.   Lancet Respiratory Medicine

Rapid Improvement After Starting Elexacaftor-tezacaftor-ivacaftor in Patients with Cystic Fibrosis and Advanced Pulmonary Disease

(2021) Pierre-Régis Burgel et al.   AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

A Phase 3 Open-Label Study of ELX/TEZ/IVA in Children 6 Through 11 Years of Age With CF and at Least One F508del Allele

(2021) Edith T. Zemanick et al.   AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

A new era for people with cystic fibrosis

(2021) Marlou C. Bierlaagh et al.   EUROPEAN JOURNAL OF PEDIATRICS

Efficacy and safety of elexacaftor plus tezacaftor plus ivacaftor versus tezacaftor plus ivacaftor in people with cystic fibrosis homozygous for F508del-CFTR: a 24-week, multicentre, randomised, double-blind, active-controlled, phase 3b trial

(2021) Sivagurunathan Sutharsan et al.   Lancet Respiratory Medicine

Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor for ≥24 Weeks in People With CF and ≥1 F508del Allele: Interim Results of an Open-Label Phase Three Clinical Trial

(2020) Matthias Griese et al.   AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

From Ivacaftor to Triple Combination: A Systematic Review of Efficacy and Safety of CFTR Modulators in People with Cystic Fibrosis

(2020) Andrea Gramegna et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Characterising burden of treatment in cystic fibrosis to identify priority areas for clinical trials

(2019) Gwyneth Davies et al.   Journal of Cystic Fibrosis

Answering the call to address cystic fibrosis treatment burden in the era of highly effective CFTR modulator therapy

(2019) Alex H. Gifford et al.   Journal of Cystic Fibrosis

Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial

(2019) Harry G M Heijerman et al.   LANCET

Elexacaftor–Tezacaftor–Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele

(2019) Peter G. Middleton et al.   NEW ENGLAND JOURNAL OF MEDICINE

ECFS best practice guidelines: the 2018 revision

(2018) Carlo Castellani et al.   Journal of Cystic Fibrosis

The CF-Sputum Induction Trial (CF-SpIT) to assess lower airway bacterial sampling in young children with cystic fibrosis: a prospective internally controlled interventional trial

(2018) Katherine Ronchetti et al.   Lancet Respiratory Medicine

The top 10 research priorities in cystic fibrosis developed by a partnership between people with CF and healthcare providers

(2017) Nicola J Rowbotham et al.   THORAX

Cystic fibrosis

(2016) J Stuart Elborn   LANCET

Future trends in cystic fibrosis demography in 34 European countries

(2015) Pierre-Régis Burgel et al.   EUROPEAN RESPIRATORY JOURNAL

Defining consensus: A systematic review recommends methodologic criteria for reporting of Delphi studies

(2014) Ivan R. Diamond et al.   JOURNAL OF CLINICAL EPIDEMIOLOGY

European Cystic Fibrosis Society Standards of Care: Best Practice guidelines

(2014) Alan R. Smyth et al.   Journal of Cystic Fibrosis

Treatment complexity in cystic fibrosis: Trends over time and associations with site-specific outcomes

(2013) Gregory S. Sawicki et al.   Journal of Cystic Fibrosis